Login to Your Account


Alzheimer's alive: Bionomics preclinical deal with Merck worth up to $526M

By Randy Osborne
Staff Writer

Tuesday, June 24, 2014
SAN DIEGO – In almost hushed tones to reporters gathered in a corner room of the San Diego Convention Center at BIO 2014, Bionomics Ltd. CEO Deborah Rathjen unveiled late Monday the firm's second deal in less than a year with Merck & Co. Inc., this time a potential $526 million arrangement focused on a preclinical therapy targeting Alzheimer's disease (AD).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription